ArticleDrug design, development and therapy2018

Schisandrin B protects against angiotensin II-induced endotheliocyte deficits by targeting Keap1 and activating Nrf2 pathway.

Jibo Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.